HK Stock Market Move | INSILICO (03696) rose over 9% as ISM8969/HT-001 has obtained the NMPA clinical trial approval, intended for the treatment of Parkinson's disease.

INSILICO (03696) rose over 9%, and as of the time of writing, it is up 8.1%, priced at 44.3 Hong Kong dollars, with a transaction volume of 541 million Hong Kong dollars. In news, recently, according to INSILICO's official WeChat account, INSILICO announced that the innovative oral NLRP3 inhibitor ISM8969/HT-001, co-developed with Hygtia Therapeutics, has received clinical trial approval from the China National Medical Products Administration (NMPA) for use in the treatment of Parkinson's disease. The approval follows the announcement in June 2026 of the completion of the first participant dosing in the Phase I clinical trial in Australia and marks the official launch of parallel clinical evaluations in both China and Australia. This clinical study aims to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) characteristics of ISM8969/HT-001 in a healthy participant population, as well as its preliminary efficacy in Parkinson's disease patients, laying the groundwork for subsequent clinical development. Previously, in January 2026, INSILICO announced that it had reached an exclusive licensing and collaboration agreement with Shenzhen Pengfu Fund, a subsidiary of Fosun Health Capital, and Hygtia Therapeutics to jointly advance the global development of ISM8969/HT-001. According to the agreement, both parties hold a 50% global stake in the project, and INSILICO is entitled to receive over 500 million Hong Kong dollars in upfront and milestone payments.